Sugi Predict

Sugi Predict / Compounds / SCHEMBL15547384

SCHEMBL15547384

SCHEMBL15547384

COc1cc(Oc2ccc(-n3c(C)n[nH]c3=O)cc2)ccc1C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 1/20 0.61
▸ CYP1A2 P05177 2/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ POLB P06746 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ NTRK1 P04629 3/20 0.46
▸ IGF1R P08069 3/20 0.46
▸ FGFR1 P11362 3/20 0.46
▸ NTRK2 Q16620 3/20 0.46
▸ ATM Q13315 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ AADAT Q8N5Z0 1/20 0.38
▸ TNF P01375 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939550 1.00 CYP2C9 (0.61) CYP2C9CYP1A2L3MBTL1POLBTDP1
SCHEMBL15546706 0.90 CYP1A2 (0.61) CYP2C9CYP1A2L3MBTL1POLBTDP1
SCHEMBL30939599 0.90 CYP1A2 (0.61) CYP2C9CYP1A2L3MBTL1POLBTDP1
SCHEMBL30939582 0.88 CYP2C9 (0.59) CYP2C9CYP1A2L3MBTL1POLBTDP1
SCHEMBL15547240 0.88 CYP2C9 (0.59) CYP2C9CYP1A2L3MBTL1POLBTDP1
SCHEMBL30939602 0.88 CYP2C9 (0.59) CYP2C9CYP1A2L3MBTL1POLBTDP1
SCHEMBL15546575 0.88 CYP2C9 (0.59) CYP2C9CYP1A2L3MBTL1POLBTDP1
SCHEMBL15546348 0.87 L3MBTL1 (0.58) CYP2C9CYP1A2L3MBTL1POLBTDP1
SCHEMBL15547041 0.83 CYP1A2 (0.75) CYP2C9CYP1A2L3MBTL1POLBTDP1
SCHEMBL15546346 0.83 L3MBTL1 (0.54) CYP2C9CYP1A2L3MBTL1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2852589-B1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2021-04-28 — — EP claimed
US-10160730-B2 Triazoles as KV3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2018-12-25 — — US claimed
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2025-01-16 — — US disclosed
CN-118267386-A Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-07-02 — — CN disclosed
CN-108472288-B Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-05-28 — — CN disclosed
US-11944623-B2 Modulators of Kv3 channels to treat pain AUTIFONY THERAPEUTICS LIMITED (GB) 2024-04-02 — — US disclosed
EP-3386506-B1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LTD (GB) 2024-01-24 — — EP disclosed
US-20220071998-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2022-03-10 — — US disclosed
US-11180461-B2 Triazoles as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-11-23 — — US disclosed
US-11180461-B2 Triazoles as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-11-23 — — US disclosed
US-11147813-B2 Modulators of KV3 channels to treat pain AUTIFONY THERAPEUTICS LIMITED (GB) 2021-10-19 — — US disclosed
US-20160318882-A1 TRIAZOLES AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2016-11-03 — — US disclosed
US-9422252-B2 Triazoles as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-08-23 — — US disclosed
US-9422252-B2 Triazoles as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-08-23 — — US disclosed
US-9422252-B2 Triazoles as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-08-23 — — US disclosed
US-20150111910-A1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2015-04-23 — — US disclosed
US-20150111910-A1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2015-04-23 — — US disclosed
US-20150111910-A1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2015-04-23 — — US disclosed
EP-2852589-A1 TRIAZOLES AS KV3 INHIBITORS Autifony Therapeutics Limited (GB) 2015-04-01 — — EP disclosed
WO-2013175215-A1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-11-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111910-A1 TRIAZOLES AS KV3 INHIBITORS KCNA3, KCNN3, KCNK3 CYP2C9 1027/4885CYP1A2 652/4885L3MBTL1 2580/4885
US-11147813-B2 Modulators of KV3 channels to treat pain KCNN3, KCNA3, KCND3 CYP2C9 1620/4885CYP1A2 1928/4885L3MBTL1 3475/4885
US-11180461-B2 Triazoles as Kv3 inhibitors KCNA3, KCNN3, KCNK3 CYP2C9 1027/4885CYP1A2 652/4885L3MBTL1 2580/4885
US-11944623-B2 Modulators of Kv3 channels to treat pain KCNN3, KCNA3, KCND3 CYP2C9 1646/4885CYP1A2 1958/4885L3MBTL1 3471/4885
US-10160730-B2 Triazoles as KV3 inhibitors KCNA3, KCNN3, KCNK3 CYP2C9 1027/4885CYP1A2 652/4885L3MBTL1 2580/4885
US-20220071998-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 CYP2C9 1646/4885CYP1A2 1958/4885L3MBTL1 3471/4885
US-20160318882-A1 TRIAZOLES AS KV3 INHIBITORS KCNA3, KCNN3, KCNK3 CYP2C9 1027/4885CYP1A2 652/4885L3MBTL1 2580/4885
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 CYP2C9 1646/4885CYP1A2 1958/4885L3MBTL1 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.